Form of human p53 protein during nuclear transport in Xenopus laevis embryos

Experimental Cell Research

Volumn 258, Issue 1, 2000, Pages 152-161

  Hara, Toshiko ^a,b   Arai, Ken Ichi ^b   Koike, Katsuro ^a  

^a CANCER INSTITUTE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Dominant negative effect; mRNA microinjection; Nuclear localization signal (NLS); p53 protein import; Xenopus embryo

Indexed keywords

ISOPROTEIN; MONOMER; MUTANT PROTEIN; OLIGOMER; PROTEIN P53;

ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; EMBRYO; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; XENOPUS LAEVIS;

ANIMALIA; XENOPUS LAEVIS;

EID: 0034632056     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.2000.4926     Document Type: Article

References (42)

1. Friedman P. N., Chen X., Bargonetti J., Prives C. The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc. Natl. Acad. Sci. USA. 90:1993;3319-3323.
2. Halazonetis T. D., Kandil A. N. Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J. 12:1993;5057-5064.
3. El-Deiry W. S., Kern S. E., Pietenpol J. A., Kinzler K. W., Vogelstein B. Definition of a consensus binding site for p53. Nature Genet. 1:1992;45-49.
4. Ko L. J., Prives C. p53: Puzzle and paradigm. Genes Dev. 10:1992;1054-1072.
5. Cho Y., Gorina S., Jeffrey P. D., Pavletich N. P. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science. 265:1994;346-355.
6. Jeffrey P. D., Gorina S., Pavletich N. P. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science. 267:1995;1498-1502.
7. Hershowitz I. Functional inactivation of genes by dominant negative mutations. Nature. 329:1987;219-222.
8. Milner J., Medcalf E. A. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell. 65:1991;765-774.
9. Brachmann R., Vidal M., Boeke J. Dominant-negative p53 mutations selected in yeast hit cancer hot spots. Proc. Natl. Acad. Sci. USA. 93:1996;4091-4095.
10. Chene P., Mittl P., Grutter M. In vitro structure-function analysis of the beta-strand 326-333 of human p53. J. Mol. Biol. 273:1997;873-881.
11. Tarunina M., Grimaldi M., Ruaro E., Pavlenko M., Schneider C., Jenkins J. R. Selective loss of endogenous p21 waf1/cip1 induction underlies the G1 checkpoint defect of monomeric p53 proteins. Oncogene. 13:1996;589-598.
12. Kay B. K. Injection of oocytes and embryos. Kay B. K., Peng H. B. Methods in Cell Biology. 1991;Academic Press, San Diego.
13. Adam S. A., Marr R. S., Gerace L. Nuclear protein import in permeabilized mammalian cells requires soluble cytoplasmic factors. J. Cell Biol. 111:1990;807-816.
14. Gorlich D., Vogel F., Mills A. D., Hartmann E., Laskey R. A. Distinct functions for the two importin subunits in nuclear protein import. Nature. 377:1995;246-248.
15. Gorlich D., Prehn S., Laskey R. A., Hartmann E. Isolation of a protein that is essential for the first step of nuclear protein import. Cell. 79:1994;767-778.
16. Imamoto N., Shimamoto T., Takao T., Tachibana T., Kose S., Matsubae M., Sekimoto T., Shimonishi Y., Yoneda Y. In vivo evidence for involvement of a 58 kDa component of nuclear pore-targeting complex in nuclear protein import. EMBO J. 14:1995;3617-3626.
17. Moore M. S., Blobel G. The GTP-binding protein Ran/TC4 is required for protein import into the nucleus. Nature. 365:1993;661-663.
18. Gorlich D., Pante N., Kutay U., Aebi U., Bischoff F. Identification of different roles for RanGDP and RanGTP in nuclear protein import. EMBO J. 15:1996;5584-5594.
19. Shaulsky G., Goldfinger N., Ben-Ze'ev A., Rotter V. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol. Cell Biol. 10:1990;6565-6577.
20. Shaulsky G., Goldfinger N., Tosky M. S., Levine A. J., Rotter V. Nuclear localization is essential for the activity of p53 protein. Oncogene. 6:1991;2055-2065.
21. Moll U. M., Riou G., Levine A. J. Two distinct mechanisms alter p53 in breast cancer: Mutation and nuclear exclusion. Proc. Natl. Acad. Sci. USA. 89:1992;7262-7266.
22. Bosari S., Viale G., Bossi P., Maggioni M., Coggi G., Murray J. J., Lee A. K. Cytoplasmic accumulation of p53 protein: An independent prognostic indicator in colorectal adenocarcinomas. J. Natl. Cancer Inst. 86:1994;681-687.
23. Ostermeyer A. G., Runko E., Winkfield B., Ahn B., Moll U. M. Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptide. Proc. Natl. Acad. Sci. USA. 93:1996;15190-15194.
24. Ueda H., Ullrich S. J., Gangemi J. D., Kappel C. A., Ngo L., Feitelson M. A., Jay G. Functional inactivation but not structural mutation of p53 causes liver cancer. Nature Genet. 9:1995;41-47.
25. Takada S., Kaneniwa N., Tsuchida N., Koike K. Cytoplasmic retention of the p53 tumor suppressor gene product is observed in the hepatitis B virus X gene-transfected cells. Oncogene. 15:1997;1895-1901.
26. Baeuerle P., Baltimore D. NF-kappa B: Ten years after. Cell. 87:1996;13-20.
27. Baldwin A. J. The NF-kappa B and I kappa B proteins: New discoveries and insights. Annu. Rev. Immunol. 14:1996;649-683.
28. Meyer B., Malim M. The HIV-Rev trans-activator shuttles between the nucleus and cytoplasm. Genes Dev. 8:1994;1538-1547.
29. Szilvay A., Brokstad K., Kopperud R., Haukenes G., Kalland K. Nuclear export of the human immunodeficiency virus type 1 nucleocytoplasmic shuttle protein Rev is mediated by its activation domain and is blocked by transdominant negative mutants. J. Virol. 69:1995;3315-3323.
30. Stauber R., Gaitanaris G., Pavlakis G. Analysis of trafficking of Rev and transdominant Rev proteins in living cells using green fluorescent protein fusions: Transdominant Rev blocks the export of Rev from the nucleus to the cytoplasm. Virology. 213:1995;439-449.
31. Szilvay A., Brokstad K., Boe S., Haukenes G., Kalland K. Oligomerization of HIV-1 Rev mutants in the cytoplasm and during nuclear import. Virology. 235:1997;73-81.
32. Middeler G., Zerf K., Jenovai S., Thulig A., Tschodrich-Rotter M., Kubitscheck U., Peters R. The tumor suppressor p53 is subject to both nuclear import and export, and both are fast, energy-dependent and lectin-inhibited. Oncogene. 14:1997;1407-1417.
33. Stommel J., Marchenko N., Jimenez G., Moll U., Hope T., Wahl G. A leucine-rich nuclear export signal in the p53 tetramerization domain: Regulation of subcellular localization and p53 activity by NES masking. EMBO J. 18:1999;1660-1672.
34. Harland R. M. In situ hybridization: An improved whole-mount method for Xenopus embryos. Kay B. K., Peng H. B. Methods in Cell Biology. 1991;Academic Press, San Diego.
35. Kern S., Kinzler K., Bruskin A., Jarosz D., Friedman P., Prives C., Vogelstein B. Identification of p53 as a sequence-specific DNA-binding protein. Science. 252:1991;1708-1711.
36. Weintraub H., Hauschka S., Tapscott S. The MCK enhancer contains a p53 responsive element. Proc. Natl. Acad. Sci. USA. 88:1991;4570-4571.
37. Masuda H., Miller C., Koeffler H., Battifora H., Cline M. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc. Natl. Acad. Sci. USA. 84:1987;7716-7719.
38. Peng H. B. Solutions and protocols. Kay B. K., Peng H. B. Methods in Cell Biology. 1991;Academic Press, San Diego.
39. Nieuwkoop P. D., Faber J. Normal Table of Xenopus laevis. 1969;North Holland, Amsterdam.
40. Takada S., Koike K. Trans-activation function of a 3′ truncated X gene-cell fusion product from integrated hepatitis virus DNA in chronic hepatitis tissues. Proc. Natl. Acad. Sci. USA. 87:1990;5628-5632.
41. Vize P. D., Melton D. A., Hemmati-Brivanlou A., Harland R. M. Assays for Gene Function in Developing Xenopus Embryos. 1991;Academic Press, San Diego.
42. Hoever M., Clement J. H., Wedlich D., Montenarh M., Knochel W. Overexpression of wild-type p53 interferes with normal development in Xenopus laevis embryos. Oncogene. 9:1994;109-120.